---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-030168"
form_type: "8-K"
ticker: "CYCN"
cik: "0001755237"
company_name: "Cyclerion Therapeutics, Inc."
filed_at: "2023-06-27T23:59:59+00:00"
generated_at: "2026-06-13T16:25:42.288381+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# COO Cheryl Gault resigns; effective at close of asset sale to JW Celtics

## Summary
- Cheryl Gault resigned as COO effective on closing of the proposed sale of certain assets to JW Celtics Investment Corp.
- Separation agreement provides six months of base salary and COBRA subsidies; stock option exercise period extended to 24 months.
- Chairman Errol De Souza thanked Gault for her service to operations and the sale transaction.

## SEC filing metadata
- accession: 0000950170-23-030168
- form_type: 8-K
- ticker: CYCN
- cik: 0001755237
- company_name: Cyclerion Therapeutics, Inc.
- filed_at: 2023-06-27T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1755237/000095017023030168/0000950170-23-030168-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1755237/000095017023030168/cycn-20230626.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-030168
- JSON: https://secwatch.observer/filing/0000950170-23-030168.json
- Plain text: https://secwatch.observer/filing/0000950170-23-030168.txt

## Key facts
- Executive change
  Cheryl Gault resigned as Chief Operating Officer at Cyclerion Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Operating Officer
  source text: On June 26, 2023, Cheryl Gault announced her resignation as the Chief Operating Officer of Cyclerion Therapeutics, Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1755237/000095017023030168/0000950170-23-030168-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.